OakChart

Femasys Inc

FEMYHealthcare·Medical Instruments & Supplies·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.50+0.07 (4.90%)
2026-11-11 22:53 CET
Market cap
11.98 USD m
Revenue, TTM
2.30 USD m
Net income, TTM
-12.29 USD m
Free cash flow, TTM
-18.07 USD m
EPS diluted, TTM
-4.62
P/E
-
Compare

Price

FEMY against its 20, 50 and 200-day averages
2050200beatearnings
2.505.007.5010.0012.5018.4M36.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FEMYclose 1.5020-day 1.4850-day 2.02200-day 5.681.50

93.2% under the 52-week high of 22.20 on 11 Nov 2025. 52-week low 1.26 on 5 Nov 2026. Last 15 sessions, 33.9% high to low

Volume 0.12× normal · the line is the 50-bar volume average

Profile

FEMY
52-week range, 1% of the way up
1.2522.20

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Employees54
IPOJun 18, 2021
Beta-2.17
ATR, 14d0.16
Rel volume0.12
Short float0.61%
Insider own3.43%
Inst own52.64%

Snapshot

6 groups

Valuation

Index-
Market Cap12.57M
Enterprise Value15.92M
Income-12.29M
Sales2.30M
Book/sh1.33
Cash/sh0.17
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees54
IPOJun 18, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S5.46
P/B1.13
P/C8.73
P/FCF-
EV/EBITDA-
EV/Sales6.92
Quick Ratio0.55
Current Ratio2.14
Debt/Eq1.19
LT Debt/Eq1.07
Option/ShortNo / Yes

Earnings

EPS (ttm)-4.62
EPS next Y-2.12
EPS next Q-0.60
EPS this Y72.34%
EPS next Y18.27%
EPS next 5Y44.87%
EPS past 3/5Y21.27% 4.34%
Sales past 3/5Y23.88% 17.18%
EPS Y/Y TTM73.27%
Sales Y/Y TTM21.86%
EPS Q/Q58.08%
Sales Q/Q-18.92%
EarningsAug 14 AMC
EPS/Sales Surpr.-1.53% -54.59%

Ownership

Insider Own3.43%
Insider Trans17.07%
Inst Own52.64%
Inst Trans34.06%
ROA-94.25%
ROE-443.65%
ROIC-147.17%
Gross Margin25.45%
Oper. Margin-763.90%
Profit Margin-534.27%
SMA201.69%
SMA50-25.86%
SMA200-73.60%
Trades-

Technical

Shs Outstand8.38M
Shs Float8.09M
Short Float0.61%
Short Ratio0.07
Short Interest0.05M
52W High22.20 -93.24%
52W Low1.25 19.52%
Volatility10.03% 10.96%
ATR (14)0.16
RSI (14)42.88
Beta-2.17
Rel Volume0.12
Avg Volume710.78K
Volume81,921

Performance

Perf Week4.17%
Perf Month-14.77%
Perf Quarter-34.50%
Perf Half Y-80.34%
Perf YTD-86.98%
Perf Year-92.03%
Perf 3Y-93.85%
Perf 5Y-98.99%
Perf 10Y-
Recom1.00
Target Price16.50
Prev Close1.43
Price1.50
Change %4.90%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Nov 20, 2025InitiatedLLaidlawBuy$6.50+333.3%

Peers

Mkt cap
TickerCompanyMkt cap
UTMDUtah Medical Products Inc208.06M
COOCooper Companies Inc11.97B
DAREDare Bioscience Inc13.65M
IVFINVO Fertility Inc3.21M
OGNOrganon & Co3.65B
TXMDTherapeuticsMD Inc21.41M
NIVFNewGenIvf Group Ltd0.37M
PRGOPerrigo Company plc2.30B
SERASera Prognostics Inc77.15M
NTRANatera Inc46.38B

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Mifek Jeffrey GeraldChief Clinical-Medical AffairsAug 07 '26Buy3.203,12510,0003,125Aug 11 08:54 PM
Sipos Jeremy AlexanderChief Technology OfficerAug 07 '26Buy3.203,12510,0003,125Aug 11 08:44 PM
Canning John CharlesChief Operating OfficerAug 07 '26Buy3.204,37514,0004,375Aug 11 08:40 PM
Elefant DovChief Financial OfficerAug 07 '26Buy3.2015,62550,00015,625Aug 11 08:37 PM
Lee-Sepsick KathyChief Executive OfficerAug 07 '26Buy3.2015,62550,00015,625Aug 11 08:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Femasys Appoints John Moorhead to Board of Directors (GlobeNewswire)
  • Femasys Partners with SandsRx Pharmacy to Support FemaSeed Fertility Portfolio Launch to OB/GYNs (GlobeNewswire)
  • Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control (GlobeNewswire) -11.36%
  • Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands (InvestorsHub)
  • Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo (GlobeNewswire)
  • Femasys Advances OB/GYN Expansion with Adoption of FemaSeed Fertility Portfolio by Minnesota Women's Care (GlobeNewswire)
  • Femasys Partners with CapexMD to Expand Patient Access to FemaSeed Fertility Portfolio (GlobeNewswire) +5.60%
  • Femasys Partners with UNC Health to Introduce Its FemaSeed Fertility Portfolio Across Statewide OB/GYN Care Locations (GlobeNewswire)
  • FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology Retail Sees 500% Upside Potential (Stocktwits) +23.18%
  • Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc (InvestorsHub)
  • Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc (GlobeNewswire)
  • Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update (GlobeNewswire) -5.68%
  • Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents (GlobeNewswire)
  • Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million (GlobeNewswire) -9.83%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-1.330-1.310-1.3300.330.733
2026Q12026-05-080.000-1.3330.0840.420.773
2025Q42026-03-31-1.254-1.666-1.3260.811.063
2025Q32025-11-14-2.000-2.300-2.0450.731.352
2025Q22025-08-08-3.200-3.266-3.1760.411.023
2025Q12025-05-08-4.600-4.000-4.6890.341.143
2024Q42025-03-27-4.600-3.700-4.4950.581.664
2024Q32024-11-12-4.800-4.000-4.8660.550.684
2024Q22024-08-08-4.200-3.250-4.2170.220.784
2024Q12024-05-09-3.400-3.800-3.3060.270.783
2023Q42024-03-28-4.000-4.250-4.0730.220.244
2023Q32023-11-14-5.200-4.350-5.2960.240.284
2023Q22023-08-10-4.400-3.850-4.4150.320.354
2023Q12023-05-11-5.000-5.200-4.9630.290.341
2022Q42023-03-30-5.000-5.200-4.9040.240.374
2022Q32022-11-10-5.000-4.700-5.0500.350.354

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-22.400-18.400-12.7721.181.20
2022FY-19.200-19.600-19.3051.211.32
2023FY-18.600-18.400-18.5221.071.13
2024FY-17.000-16.050-16.9001.632.71
2025FY-9.400-10.467-9.4002.292.55
2026FY--2.600--2.09
2027FY--2.125--9.44
2028FY--1.575--19.96
2029FY--0.555--45.51
2030FY-2.490--94.46

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-312010.620.440.80
2026Q3S2026-10-282020.620.440.80
2026Q3S2026-09-153020.760.441.05
2026Q3S2026-08-173020.810.581.05
2026Q3S2026-08-153001.100.751.50
2026Q3S2026-08-143001.100.751.50
2026Q3S2026-07-253001.100.751.50
2026Q3S2026-06-153021.100.751.50
2026Q3S2026-05-113031.100.751.50
2026Q3S2026-04-133021.501.031.98
2026Q3S2026-04-012011.271.031.50
2026Q3S2026-03-022001.971.602.34
2026Q3S2025-11-171002.342.342.34
2026Q3S2025-11-111002.342.342.34

Estimate history

EPS, annual-19.167-11.759-12.772-19.305-18.522-16.9-9.42-4.618
Period2019202020212022202320242025TTM
EPS, quarterly-4.217-4.866-4.495-4.689-3.176-2.045-1.3260.084-1.331
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.9291.0381.181.2061.0721.6292.2932.3
Period2019202020212022202320242025TTM
Sales, quarterly0.2210.5550.5820.3410.4090.7290.8130.4250.332
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.5880.5880.590.591.0831.1682.983.024
Period2019202020212022202320242025MRQ
Shares, quarterly1.1121.1121.1681.3541.6292.3652.983.023.024
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue2.302.291.631.071.211.181.040.93
Cost of Goods Sold Incl. D&A1.711.721.421.291.331.331.411.32
Gross Profit0.590.570.21-0.22-0.12-0.15-0.37-0.39
Selling, General and Administrative Excl. Other18.1518.1618.0014.2911.488.186.5611.25
Research and Development6.457.588.227.215.814.084.136.91
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-17.57-17.59-17.79-14.51-11.60-8.34-6.93-11.64
Interest Expense1.592.181.600.170.010.020.010.01
Unusual Expense-7.19-1.230.000.000.000.000.000.00
Net Income Before Taxes-11.76-18.63-18.81-14.24-11.39-7.53-6.91-11.27
Income Taxes0.010.000.010.000.010.000.000.00
Consolidated Net Income-12.29-18.63-18.82-14.25-11.39-7.54-6.91-11.27
Net Income From Continuing Operations-12.29-18.63-18.82-14.25-11.39-7.54-6.91-11.27
Net Income-12.29-18.63-18.82-14.25-11.39-7.54-6.91-11.27
EPS (Recurring)-5.16-9.86-16.90-18.52-19.31-12.77-11.76-19.17
EPS (Basic, Before Extraordinaries)-4.60-9.42-16.90-18.52-19.31-12.77-11.76-19.17
EPS (Diluted)-4.62-9.42-16.90-18.52-19.31-12.77-11.76-19.17
EBITDA-16.75-16.74-16.91-13.60-10.71-7.37-5.83-10.54
Non-Operating Income (Expense)0.20-0.090.580.430.230.820.030.38
Other After Tax Adjustments-0.520.000.000.000.000.000.000.00
Stock Option Compensation Expense0.550.620.350.530.180.140.230.26
Price To Sales Ratio6.109.9415.0413.998.8139.02--
Gross Margin25.4524.8713.03-20.16-10.35-13.14-35.59-41.90
Operating Margin-763.90-766.95-1,091.75-1,353.43-961.71-706.70-667.99-1,252.57
Net Margin-534.27-812.27-1,155.03-1,329.06-944.62-638.97-666.24-1,213.26
Shares Outstanding3.022.981.171.080.590.590.590.59
Market Capitalization11.9811.9825.6915.5910.6346.0442.72-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.330.420.810.730.410.340.580.55
Cost of Goods Sold Incl. D&A0.340.360.510.500.370.330.410.41
Gross Profit-0.010.070.300.220.040.010.170.15
Selling, General and Administrative Excl. Other5.064.294.933.883.895.474.895.27
Research and Development1.951.311.811.381.412.972.172.30
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.07-4.22-4.62-3.65-3.85-5.46-4.72-5.12
Interest Expense0.190.180.690.530.490.460.440.41
Unusual Expense-0.76-5.20-1.230.000.000.000.000.00
Net Income Before Taxes-4.470.85-3.94-4.19-4.59-5.90-5.11-5.41
Income Taxes0.000.000.010.000.00-0.000.010.00
Consolidated Net Income-4.470.33-3.95-4.19-4.59-5.90-5.12-5.41
Net Income From Continuing Operations-4.470.33-3.95-4.19-4.59-5.90-5.12-5.41
Net Income-4.470.33-3.95-4.19-4.59-5.90-5.12-5.41
EPS (Recurring)-1.49-0.85-1.62-2.05-3.18-4.69-4.49-4.87
EPS (Basic, Before Extraordinaries)-1.330.10-1.33-2.05-3.18-4.69-4.49-4.87
EPS (Diluted)-1.330.08-1.33-2.05-3.18-4.69-4.49-4.87
EBITDA-4.87-4.02-4.42-3.44-3.64-5.24-4.50-4.90
Non-Operating Income (Expense)0.020.050.14-0.01-0.240.020.050.12
Other After Tax Adjustments0.00-0.520.000.000.000.000.000.00
Stock Option Compensation Expense0.170.150.050.170.140.290.110.10
Price To Sales Ratio6.1013.8114.987.0114.7818.5015.3919.58
Gross Margin-2.4215.4937.2330.788.852.0329.3926.73
Operating Margin-1,526.66-994.03-568.33-500.93-941.09-1,600.11-812.03-922.39
Net Margin-1,346.8177.35-485.66-575.11-1,120.52-1,727.94-881.00-974.73
Shares Outstanding3.023.022.982.371.631.351.171.11
Market Capitalization11.9825.3834.3416.6731.4633.8625.6924.68

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments9.273.4521.7212.9624.783.327.41
Short Term Receivables0.620.490.100.080.080.130.08
Inventories5.743.050.670.440.210.130.17
Other Current Assets0.831.040.700.660.560.280.37
Total Current Assets16.468.0223.1814.1325.633.868.04
Net Property, Plant & Equipment3.193.403.491.802.262.893.86
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets0.130.070.000.000.030.070.16
Deferred Tax Assets----20.38--
Other Assets0.940.951.090.960.660.790.58
Total Assets20.7212.4527.7616.9048.967.6112.65
Short Term Debt Incl. Current Port. of LT Debt0.495.920.410.520.591.060.47
Accounts Payable1.831.421.140.510.450.670.48
Other Current Liabilities1.321.241.510.500.661.150.34
Total Current Liabilities3.648.583.051.531.692.891.29
Long Term Debt4.211.526.290.030.4056.3456.59
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities----20.38--
Other Liabilities7.010.040.050.100.150.200.15
Total Liabilities14.8510.149.401.6522.6259.4258.02
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.020.02
Common Equity5.872.3018.3515.2426.33-51.83-45.39
Total Shareholders Equity5.872.3018.3515.2426.33-51.82-45.37
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity5.872.3018.3515.2426.33-51.82-45.37
Total Liabilities & Stockholders Equity20.7212.4527.7616.9048.967.6112.65
Book Value Per Share1.971.9716.9525.8344.62-88.14-77.18
Tangible Book Value Per Share1.921.9216.9525.8244.57-88.25-77.46
Full-Time Employees547132342724-
Price to Book Ratio1.0711.151.490.591.751.49-
Return on Assets-112.32-93.61-63.81-34.61-26.65-68.29-
Return on Equity-455.80-182.18-84.82-54.81---
Return on Invested Capital-184.83-492.26-57.81-74.61-28.19-153.00-100.51
Quick Ratio2.950.587.378.9615.021.296.12
Current Ratio4.530.937.599.2515.151.346.25

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-11.77-18.63-18.82-14.25-11.39-7.54-6.91-11.27
Depreciation0.820.850.870.910.890.961.101.09
Other Funds (Non Cash)-5.441.141.650.840.23-0.620.320.25
Funds from Operations-16.39-16.63-16.30-12.50-10.27-7.20-5.49-9.93
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-1.26-2.06-3.141.22-0.46-0.730.56-1.08
Cash from Operating Activities-17.65-18.69-19.44-11.28-10.73-7.93-4.93-11.01
Capital Expenditures-0.54-0.63-0.85-0.14-0.41-0.31-0.03-0.70
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.001.0013.01
Purchase of Investments0.000.000.000.000.000.000.00-9.12
Sale Or Maturity of Investments0.000.000.000.000.000.001.0022.14
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.54-0.63-0.85-0.14-0.41-0.310.9712.32
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock13.2021.922.0314.48-0.1530.160.080.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock13.2021.922.0314.48-0.1530.160.080.00
Proceedsfrom Stock Options1.8310.511.9610.79-0.1530.160.080.00
Issuance or Reduction of Debt, Net3.223.220.005.71-0.51-0.440.81-0.11
Change in Long Term Debt3.223.220.005.71-0.51-0.440.81-0.11
Issuance of Long Term Debt12.0012.000.006.850.000.000.810.00
Reduction of Long Term Debt-8.78-8.780.00-1.14-0.51-0.440.00-0.11
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities16.4225.142.0320.18-0.6829.700.87-0.13
Net Change in Cash-1.775.81-18.268.75-11.8221.46-3.091.18
Free Cash Flow-18.07-19.22-20.21-11.42-11.14-8.24-4.94-11.60
Preferred Dividends (Cash Flow)-0.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments1.445.399.274.573.223.82
Short Term Receivables0.150.170.620.570.250.23
Inventories6.196.115.745.785.233.86
Other Current Assets0.550.680.831.321.051.22
Total Current Assets8.3312.3416.4612.259.759.13
Net Property, Plant & Equipment2.923.103.193.173.143.25
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.120.120.130.130.060.06
Other Assets0.920.920.940.740.830.84
Total Assets12.2916.5020.7216.2913.7813.28
Short Term Debt Incl. Current Port. of LT Debt0.470.480.497.286.586.27
Accounts Payable2.341.601.832.173.262.33
Other Current Liabilities1.081.081.321.091.121.24
Total Current Liabilities3.893.163.6410.5410.969.84
Long Term Debt4.324.254.211.151.271.39
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.051.807.010.040.040.05
Total Liabilities8.269.2114.8511.7312.2711.28
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.037.295.874.561.512.00
Total Shareholders Equity4.037.295.874.561.512.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.037.295.874.561.512.00
Total Liabilities & Stockholders Equity12.2916.5020.7216.2913.7813.28
Book Value Per Share1.332.411.971.930.931.47
Tangible Book Value Per Share1.292.371.921.870.891.43
Full-Time Employees--54---
Price to Book Ratio1.073.485.853.6620.8716.96
Return on Assets-94.25-83.31-112.32-124.24-123.41-112.16
Return on Equity-443.65-267.10-455.80-376.23-329.45-239.87
Return on Invested Capital-53.532.85-39.19-73.54-165.17-173.97
Quick Ratio0.551.982.950.610.410.54
Current Ratio2.143.914.531.160.890.93

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.470.85-3.95-4.19-4.59-5.90
Depreciation0.200.200.210.210.210.22
Other Funds (Non Cash)-0.37-4.87-0.810.600.590.76
Funds from Operations-4.64-3.82-4.55-3.38-3.78-4.92
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.70-0.320.36-2.00-0.570.15
Cash from Operating Activities-3.94-4.14-4.19-5.39-4.35-4.77
Capital Expenditures-0.02-0.08-0.20-0.24-0.10-0.10
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.08-0.20-0.24-0.10-0.10
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.020.345.777.073.855.23
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.020.345.777.073.855.23
Proceedsfrom Stock Options0.020.34-5.607.073.815.23
Issuance or Reduction of Debt, Net0.000.003.31-0.090.000.00
Change in Long Term Debt0.000.003.220.000.000.00
Issuance of Long Term Debt0.000.0012.000.000.000.00
Reduction of Long Term Debt0.000.00-8.780.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.020.349.086.983.855.23
Net Change in Cash-3.94-3.884.701.35-0.600.37
Free Cash Flow-3.95-4.22-4.33-5.58-4.45-4.86

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 1.63M 2025: 2.29M
Non-US2024: 555.60K 2025: 899.76K
United States2024: 1.07M 2025: 1.39M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.61%0.0M8.1M724.34K
2026-10-152.03%0.2M8.1M718.47K
2026-09-307.14%0.6M8.1M714.61K
2026-09-157.57%0.6M8.1M718.94K
2026-08-317.34%0.6M8.1M709.76K
2026-08-145.38%0.4M8.1M110.80K
2026-07-319.63%0.3M2.8M69.83K
2026-07-157.06%0.2M2.8M62.10K
2026-06-306.92%0.2M2.8M60.34K
2026-06-157.22%0.2M2.8M59.07K
2026-05-296.05%0.2M2.7M50.46K
2026-05-153.56%0.1M2.7M24.91K
2026-04-303.52%0.1M2.7M25.74K
2026-04-153.52%0.1M2.7M33.60K
2026-03-313.73%0.1M2.7M38.09K
2026-03-133.70%0.1M2.7M47.54K
2026-02-273.62%0.1M2.7M53.48K
2026-02-133.86%0.1M2.7M70.03K
2026-01-304.07%0.1M2.7M202.13K
2026-01-153.58%0.1M2.7M310.71K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-053Initial statement of beneficial ownership of securities2026-10-30SEC
2026-11-028-KCurrent report2026-10-30SEC
2026-10-15SCHEDULE 13GSEC
2026-09-29424B3SEC
2026-09-28EFFECTEffectiveness filing by commission orderSEC
2026-09-03S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-31SCHEDULE 13GSEC
2026-08-20DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-17SCHEDULE 13DSEC
2026-08-14SCHEDULE 13GSEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-08-113Initial statement of beneficial ownership of securities2026-07-06SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-114Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-118-KCurrent report2026-08-05SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-06-248-KCurrent report2026-06-23SEC
2026-06-058-KCurrent report2026-06-05SEC
2026-06-048-KCurrent report2026-06-04SEC
2026-05-138-KCurrent report2026-05-13SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08134.00K500
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Dauntless Investment Group, LLC61.86%
VANGUARD CAPITAL MANAGEMENT LLC2.06%
Creek Drive Management Group LLC1.87%
JANE STREET GROUP, LLC1.74%
CITADEL ADVISORS LLC0.56%
VANGUARD FIDUCIARY TRUST CO0.41%
GEODE CAPITAL MANAGEMENT, LLC0.37%
Warberg Asset Management LLC0.26%
UBS Group AG0.14%
OSAIC HOLDINGS, INC.0.08%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.14%
VANGUARD EXTENDED MARKET INDEX FUND0.93%
Fidelity Extended Market Index Fund0.18%
Fidelity Nasdaq Composite Index Fund0.05%
Fidelity Series Total Market Index Fund0.05%
Fidelity Total Market Index Fund0.03%
Blackstone Alternative Multi-Strategy Fund-0.02%

OakChart. FEMY. Cached 15 minutes.